CC
BMRN icon

CQS Cayman’s BioMarin Pharmaceuticals BMRN Stock Holding History

CQS Cayman’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$4.41M Sell
65,474
-3,000
-4% -$231K 0.19% 85
2019
Q2 		$5.86M Buy
68,474
+26,780
+64% +$2.29M 0.23% 70
2019
Q1 		$3.7M Sell
41,694
-27,400
-40% -$2.54M 0.17% 70
2018
Q4 		$5.88M Buy
69,094
+10,394
+18% +$989K 0.41% 49
2018
Q3 		$5.69M Sell
58,700
-117,800
-67% -$11.8M 0.27% 58
2018
Q2 		$16.6M Buy
176,500
+45,000
+34% +$3.94M 0.89% 38
2018
Q1 		$10.7M Buy
131,500
+5,000
+4% +$429K 0.49% 55
2017
Q4 		$11.3M Buy
126,500
+11,000
+10% +$956K 0.71% 46
2017
Q3 		$10.8M Buy
115,500
+111,900
+3,108% +$9.89M 0.72% 49
2017
Q2 		$327K Sell
3,600
-400
-10% -$36.4K 0.02% 109
2017
Q1 		$351K Buy
+4,000
New +$356K 0.03% 109
2016
Q4 		– Sell
-3,750
Closed -$347K – 118
2016
Q3 		$347K Sell
3,750
-46,378
-93% -$4.37M 0.03% 126
2016
Q2 		$3.9M Sell
50,128
-12,792
-20% -$1.09M 0.34% 63
2016
Q1 		$5.19M Buy
62,920
+22,320
+55% +$1.82M 0.52% 48
2015
Q4 		$4.25M Buy
40,600
+11,100
+38% +$1.16M 0.29% 65
2015
Q3 		$3.11M Sell
29,500
-10,500
-26% -$1.4M 0.26% 73
2015
Q2 		$5.47M Sell
40,000
-83,000
-67% -$10.3M 0.33% 72
2015
Q1 		$15.3M Buy
123,000
+48,000
+64% +$5.09M 0.72% 27
2014
Q4 		$6.78M Sell
75,000
-10,000
-12% -$832K 0.45% 57
2014
Q3 		$6.13M Buy
+85,000
New +$5.59M 0.36% 69

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

CQS Cayman's BMRN Position: Q3 2019 in Review

CQS Cayman reduced its BioMarin Pharmaceuticals (BMRN) stake by 4.4% in Q3 2019, selling an estimated $231K and leaving 65,474 shares worth $4.41M. The position accounts for 0.19% of the portfolio, ranked #85.

CQS Cayman first reported a position in BMRN in Q3 2014 and has held it in 20 quarters since. The position peaked at $16.6M in Q2 2018. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • CQS Cayman held 65,474 shares of BioMarin Pharmaceuticals worth $4.41M as of Q3 2019.
  • CQS Cayman sold 3,000 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $231K.
  • BioMarin Pharmaceuticals made up 0.19% of CQS Cayman's portfolio in Q3 2019, its #85 holding.
  • CQS Cayman first reported a position in BioMarin Pharmaceuticals in Q3 2014 and has held it in 20 quarters since.
  • CQS Cayman's BioMarin Pharmaceuticals position peaked at $16.6M in Q2 2018.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on CQS Cayman's 13F filing for Q3 2019, filed 12 Nov 2019.